OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

Charity Number: 1176307

The ecancer Global Foundation

FINANCIAL STATEMENTS

For the Year Ended 31 December 2023

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

C O N T E N T S
Page
LEGAL AND ADMINISTRATIVE DETAILS 1
TRUSTEES’ REPORT 2 - 5
AUDITOR’S REPORT 6 - 8
STATEMENT OF FINANCIAL ACTIVITIES 9
BALANCE SHEET 10
STATEMENT OF CASH FLOWS 11
NOTES TO THE FINANCIAL STATEMENTS
12-17

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

Principal address

Independent Examiners

The ecancer Global Foundation 13 King Square Avenue Bristol BS2 8HU

Hazlewoods LLP Windsor House Bayshill Road Cheltenham GL50 3AT

Trustees:

The trustees who served during the year were:

Emily Sarah Kobbe Penelope Jane Crocker Professor Richard Sullivan James Isola Cristian Herra Groesbeck Parham

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The e cancer Global Foundation TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Message from the chair

As we look back on 2023, I am delighted to share the incredible strides ecancer has made in advancing global cancer education. The impressive team at ecancer have continued to expand our reach and impact, with a focus on providing valuable educational resources, particularly in low- and middle-income countries.

This year, we have connected with over 655,000 learners through ecancer.org , demonstrating the significant demand for accessible, high-quality cancer education. Our video library has continued to flourish with 766 new videos published and over 1.7 million views from healthcare professionals around the world. These videos, many filmed at leading oncology conferences, are a vital part of our mission to disseminate the latest developments in cancer care.

Our journal continues to support researchers, particularly in low-resource settings, with 161 articles published this year. We are particularly proud of the inclusive nature of our "pay what you can afford" model, ensuring that research is available to all, regardless of their financial means.

In addition, we have deepened our involvement in vital international research projects, such as PIONEER, the European Network of Excellence for Big Data in Prostate Cancer, and the Women, Power and Cancer Lancet Commission, which addresses gender inequality in cancer care.

Our events programme saw unprecedented success this year, with 12 events reaching healthcare professionals across the world, bringing together international and regional experts to share knowledge and improve patient outcomes.

2023 has been a challenging year financially with funds secured in previous years used to support our global events programme resulting in a deficit. The Senior Management Team have taken steps to rectify this moving forward with a renewed focus on managing resources efficiently, strengthening financial sustainability, and ensuring robust planning for 2024 and beyond.

As we look ahead to 2024, we are excited to build on our achievements and continue providing high quality education and partnerships to continue transforming cancer care globally. Thank you to all our supporters and partners for your unwavering commitment to this cause.

Professor Richard Sullivan

Chair of Trustees

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The e cancer Global Foundation TRUSTEES’ REPORT CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023

Stats: Key 2023 highlights ecancer.org - 655,000 learners

Video

Journal (ecancermedicalscience)

e-learning

News

Research projects

We are partners in the following projects funded by the EU and National Institutes of Health (USA):

Events

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The e cancer Global Foundation TRUSTEES’ REPORT CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023

Report of the Trustees

The Trustees hereby present the statutory report, with the accounts of The ecancer Global Foundation, for the year ending 31 December 2023.

The results for the year are presented in the form of a Statement of Financial Activities, which incorporates the traditional income and expenditure account, in order to comply with the Statement of Recommended Practice for Charities, and in accordance with the Charities Act 2011.

The Trust

The accounts accompanying this report are the accounts of the charitable trust. It is registered with the Charities Commission, Charity Registration number 1176307.

Charitable objectives

Our vision

A world in which every cancer patient receives the best possible care and treatment.

Our mission and future plans

e cancer's mission is to raise the standards of care for cancer patients across the world through education. Over the next 12 months, ecancer will focus on expanding the number of learners engaging with our resources as well as developing all aspects of our work to meet the needs of the global oncology community.

Public benefit statement:

The ecancer Global Foundation’s charitable purpose is carried out for the public benefit in accordance with our vision and mission. The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to the Charity Commission’s general guidance on Charities and Public Benefit.

Educational activities for healthcare professionals

The majority of the oncology professionals who engage with our educational resources do so through our open access and free website, ecancer.org. The site provides a vast knowledge bank covering every cancer type which are developed in partnership with leading global experts to meet regional educational needs. ecancer.org has been publishing free education for the oncology community since 2007 and, as such, has an established audience from around the world.

As well as ecancer.org, our ethos is to provide educational resources to the global oncology community wherever there is a need to as wide an online audience as possible. Our resources are therefore also disseminated through platforms such as YouTube, PubMed, Twitter, Facebook, LinkedIn, Scopus, Web of Science, Embase, EBSCO and Google Scholar as well as other educational partners such as the Union for International Cancer Control (UICC), the International Cancer Control Partnership and the International Society for Geriatric Oncology (SIOG).

A section of ecancer.org is dedicated to healthcare professionals in Latin America with content in predominantly in Spanish but also in Portuguese. We have native Spanish speakers who manage and maintain this section with support from our other team members.

We also publish ecancerpatient.org which is a patient-focused website that provides the latest cancer information direct from experts in an easy-to-understand format that was developed in partnership with patient groups. The goal is to empower patients to be more involved in the decision-making process when it comes to their care.

Our series of educational events in under-served areas of the world is now well established in Latin America and has launched in India with fantastic educational partners allowing us to deliver high quality education in areas of the world that need it most.

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The e cancer Global Foundation TRUSTEES’ REPORT CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023

Trustee Recruitment and training programme

The existing Trustees and CEO review any gaps in the group of Trustees on an ongoing basis, and if there is a shortage, will review suitable individuals who fit the requirements profile. Any individual is then approached and recruited, and follows the charity’s training and induction process.

Pay and remuneration is reviewed on an annual basis as part of the budgeting process, and is agreed at Trustee level.

Decision making

The charity is managed by the CEO, with support from the Senior Management Team. Key decisions likely to significantly impact the organisation are agreed by the CEO and Trustees, who review and evaluate in detail.

Risk Assessment

In accordance with the SORP requirements, the Trustees carry out wide-ranging reviews of the risks faced by the charity. These reviews look particularly at Health and Safety issues, management and financial accountability and internal security. The Trustees are satisfied that all appropriate and feasible measures have been put in place to reduce the risks to which the charity is exposed. As a consequence of this, the Trustees have greater awareness of the kinds of risks which could affect the charity and have implemented strategies to reduce such risks.

Reserves policy and financial position

As a young charity, we are currently in the process of building reserves to achieve the aims of the organisation which is to maintain free unrestricted reserves:

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

The Trustees of the Charity are required to prepare for each financial year accounts which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that period. In preparing those financial statements, the trustees are required to:

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust Deed dated 15 December 2017. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 22/10/2024

Approved by the Trustees on …………..…… and signed as authorised

…………………………….. Prof. Richard Sullivan

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation AUDITOR’S REPORT TO THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023

We have audited the financial statements of The ecancer Global Foundation for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Opinion on financial statements

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

Other information

The other information comprises the information included in the annual report, other than the financial statement and our auditor’s report thereon. The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation AUDITOR’S REPORT TO THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities Act 2011 requires us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation AUDITOR’S REPORT TO THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023

Extent to which the audit was considered capable of detecting irregularities, including fraud

Owing to the inherent limitations of an audit, there is an unavoidable risk that material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the ISA’s (UK).

In identifying and assessing risks of material mis-statement in respect of fraud, including irregularities and noncompliance with laws and regulations, our procedures included the following:

• We obtained an understanding of the legal and regulatory frameworks applicable to the company financial statements or that had a fundamental effect on the company’s operations. We determined that the most significant laws and regulations included UK GAAP, UK Companies Act 2006 and taxation laws.

• We understood how the company is complying with those legal and regulatory frameworks by making inquiries of management, those responsible for legal and compliance procedures.

• We assessed the susceptibility of the company’s financial statements to material misstatement, including how fraud might occur. Audit procedures performed by the engagement team included:

• Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;

• Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process. Detailed analysis of journals posted through the accounting system during the year to 31 December 2023 has been undertaken;

• Understanding the controls in place to prevent and detect fraud. Reliance was not placed on controls for the entirety of the audit, instead taking a substantive testing approach, however controls were in place to prevent fraud, and they appeared to be working effectively;

• Challenging assumptions and judgements made by management in its significant accounting estimates.

Use of our report

This report is made solely to the charity’s trustees, as a body, in accordance with the Charities Act 2011. Our audit work has been undertaken so that we might state to the trustees those matters we are required to state to them in an auditors’ report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

……………………… Martin Howard (Senior Statutory Auditor) For and on behalf of Hazlewoods LLP, Statutory Auditor

Windsor House Bayshill Road Cheltenham GL50 3AT

22/10/2024

Date: …………………

Hazlewoods LLP are eligible to act as auditors in terms of section 1212 of the Companies Act 2006

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The e cancer Global Foundation STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2023

INCOMING
RESOURCES
Unrestricted funds
Notes
Donations and
legacies
Grant amortisation
Charitable
Activities
E-learning
Events
Journal
Research projects
Educational video
Other Activities to
Generate
Funds
Advertising income
Total Incoming
Resources
Resources
Expended
Raising funds
Charitable
Expenditure
E-learning
Events
Journal
Research projects
Educational videos
Website
Advertising
Total Resources
Expended
2
Net movements in
funds
Transfer between
funds
Total funds
brought forward
Balance carried
forward at 31
December 2023
Unrestricted
funds
2023
£
1,022
661
-
-
11,649
-
344,851
76,668
434,851
91,386
93,966
126,280
117,890
-
395,828
94,808
577
829,349
920,735
(485,884)
(141,198)
188,645
(438,437)
Restricted
funds 2023
£
-
-
26,000
158,423
-
-
411,692
-
596,115
-
3,047
271,596
-
33,527
116,501
-
-
424,671
424,671
171,444
141,198
5,501
318,143
Total funds
2023
£
1,022
661
26,000
158,423
11,649
-
756,543
76,668
1,030,966
91,386
97,013
397,876
117,890
33,527
512,329
94,808
577
1,254,020
1,345,406
(314,440)
-
194,146
(120,294)
Total
funds
2022
£
1,083
1,322
118,199
324,552
8,004
-
773,586
109,846
1,336,592
75,008
160,587
400,265
136,654
-
455,463
98,696
67
1,251,732
1,326,740
9,851
-
184,295
194,146

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation BALANCE SHEET AT 31 DECEMBER 2023

Note
Fixed assets
3,7
Current Assets
Debtors and prepayments
4,7
Cash at bank and in hand
Less Creditors: Amounts
falling due within one year
5,7
Net Current (Liabilities) / Assets
Net (Liabilities) / Assets
Represented by:
Restricted funds:
6
Unrestricted funds
6
2023
35,225
166,217
136,053
302,270
(457,789)
(155,519)
(120,294)
318,143
(438,437)
(120,294)
2022
£
41,210
337,814
294,817
632,631
(479,695)
152,936
194,146
5,501
188,645
194,146

22/10/2024

Approved by the trustees on ………………. and signed on their behalf by:

………………….. Prof R Sullivan

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2023

2023
2022
£
£
Cash flows from operating activities
(Deficit) / surplus for the year (314,440)
9,851
Adjustments to cash flows from non-cash items
Depreciation and amortisation 10,112
6,738
(304,328)
16,589
Working capital adjustments
Decrease/(increase) in debtors 171,597
(154,359)
Decrease in creditors (21,848)
(117,455)
Cash generated from / (in) operations 149,749
(271,814)
Net cash flow from operatingactivities (154,579)
(255,225)
Cash flows from investing activities
Acquisitions of tangible assets (4,185)
(45,703)
Net cash flows from investingactivities (4,185)
(45,703)
Net (decrease)/increase in cash and cash equivalents (158,764)
(300,928)
Cash and cash equivalents at 1 January 294,817
595,745
Cash and cash equivalents at 31 December 136,053
294,817

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. Accounting Policies

Basis of Preparation

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of certain fixed assets, adopting the following principal accounting policies all of which are in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) and the Charities Act 2011.

General information

The financial statements are presented in Pounds Sterling. The charity is a public benefit charitable incorporated organisation, incorporated in England and Wales.

The address of its registered office is: 13 King Square Avenue Bristol BS2 8HU

Judgements and estimation uncertainty

The trustees consider that there are no key areas of judgement or estimation uncertainty to be disclosed in these financial statements.

Tangible fixed assets and depreciation

Tangible fixed assets are stated in the accounts at cost or revalued amount less depreciation. Depreciation is provided at rates calculated to write off the cost of each asset over its expected useful life.

Depreciation is provided to write off the cost/value of assets over their useful lives as follows:

Office equipment 5 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade receivables

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All debtors are repayable within one year and are hence included at the undiscounted amount of the cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the Charity will not be able to collect all amounts due according to the original terms of the receivables.

Trade payables

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the Charity does not have an unconditional right, at the end of the reporting year, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

Legacies, Donations and Grants Receivable

All income is recognised when receivable and when capable of financial measurement. Receipts of property investments or other gifts in kind are included at market value.

Going concern

There are no significant factors affecting the charity’s ability to continue as a going concern.

Expenditure on Charitable activities

Expenditure on Charitable activities is included in the Statement of Financial Activities on an accruals basis. Where expenditure is directly attributable to more than one activity, it is apportioned across cost categories on the basis of the proportion of income receivable relating to each activity.

Funds

Funds held by the charity are either:

Pensions

The company operates a defined contribution scheme for certain employees. The contributions are charged to revenue in the year in which they are incurred.

2. Analysis of Total Resources Expended

Charitable Expenditure
E-learning
Events
Journal
Research projects
Educational videos
Raising funds
Website and advertisements
Direct
Activities
£
-
-
103,252
33,527
-
91,386
95,385
323,550
Grant
funding
£
89,751
366,787
-
-
424,464
-
-
**881,002 **
Support
costs
(see 2a
below) £
7,262
31,089
17,638
-
84,865
-
-
**140,854 **
2023
Total
£
97,013
397,876
120,890
33,527
509,329
91,386
95,385
1,345,406
2022
Total
£
109,044
452,798
136,654
-
453,324
76,121
98,799
1,326,740

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The ecancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

Support costs are allocated on the basis of full-time equivalents.

Staff costs:
Wages and salaries
Social security costs
Pension costs
The average number of full time employees
In the period was
2023
£
528,190
50,624
37,686
616,500
Number
18
2022
£
523,293
46,849
37,969
608,111
Number
19

No employee earned £60,000 or more, and no Trustees were remunerated through the charity.

During the year, the charity made redundancy payments of £5,674 (2022 - £nil).

2a. Analysis of Support Costs

E-learning
Events
Journal
Educational videos
2023
£
7,262
31,089
17,638
84,865
140,854
2022
£
8,162
35,381
20,445
75,091
139,079

Support costs are all allocated to charitable expenditure, other than £nil (2022 - £nil) incurred in relation to raising funds within the year.

Audit fees accrued during the year was £9,300 (2022 - £3,700). No other services were provided by the auditors.

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The e cancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

3. Fixed assets

Cost
At 1 January 2023
Additions
December 31, 2023
Depreciation
At 1 January 2023
Charge for the year
December 31, 2023
Net book value
December 31, 2023
December 31, 2022
4.
Debtors
Trade debtors
Prepayments and accrued income
2023
£
160,892
5,325
166,217
Office
equipment
£
49,071
4,127
53,198
7,861
10,112
17,973
35,225
41,210
2022
£
333,522
4,292
337,814

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The e cancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

5. Creditors: Amounts falling due within one year

Trade creditors
Taxation and social security
Accruals and deferred income
Other creditors
Capital grants
2023
£
55,382
12,416
373,051
9,009
7,931
457,789
2022
£
30,990
23,791
380,450
35,872
8,592
479,695

Included within accruals and deferred income is £325,189 (2022 - £336,386) in relation to income deferred on performance-related grants. These grants are considered to contain conditions that require the charity to undertaken certain activities before it becomes fully entitled to the respective grant monies.

Reconciliation of deferred income

At 1 January 2023
Deferred income released
Additional deferred income
At 31 December 2023
Deferred income
£
336,386
(309,588)
298,391
325,189

6. Funds

General fund
Restricted
fund
E-learning
Events
Journal
Research
Educational
videos
Transfer
between funds
1 January
2023
£
188,645
-
-
-
5,501
-
-
194,146
Incoming
resources
£
434,851
26,000
158,423
-
-
411,692
1,030,966
Transfer
between
funds
£
(141,199)
-
113,173
28,026
-
-
Outgoing
resources
£
(920,734)
(3,048)
(271,596)
-
(33,527)
(116,501)
-
(1,345,406)
31 December
2023
£
(438,437)
22,952
-
-
-
295,191
(120,294)

The restricted funds are held separately as they relate to specific performance related grant funds and expenditure. They represent various projects for which the donors have specified the use of the funds. These have been grouped into various categories for the purpose of the note above.

Docusign Envelope ID: 450AFD65-9BB2-4184-AA96-B642849E0E6E

The e cancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

7. Reconciliation of funds per asset/liability

Fixed assets
Cash at bank and
in hand
Current assets
Current liabilities
Fixed assets
Cash at bank and
in hand
Current assets
Current liabilities
Unrestricted
funds
£
35,225
136,053
166,217
(132,600)
204,895
Unrestricted
funds
£
41,210
294,817
337,814
(143,309)
530,532
Restricted
funds
£
-
-
-
(325,189)
(325,189)
Restricted
funds
£
-
-
-
(336,386)
(336,386)
2023
Total
£
35,225
136,053
166,217
(457,789)
(120,294)
2022
Total
£
41,210
294,817
337,814
(479,695)
194,146